Real‐world evaluation of ocrelizumab in multiple sclerosis: A systematic review

Across its clinical development program, ocrelizumab demonstrated efficacy in improving clinical outcomes in multiple sclerosis, including annualized relapse rates and confirmed disability progression. However, as with any new treatment, it was unclear how this efficacy would translate into real‐wor...

Descripción completa

Detalles Bibliográficos
Autores principales: Montalban, Xavier, Matthews, Paul M., Simpson, Alex, Petrie, John L., Sammon, Cormac, Ramagopalan, Sreeram, Disanto, Giulio, Kuhle, Jens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014013/
https://www.ncbi.nlm.nih.gov/pubmed/36728340
http://dx.doi.org/10.1002/acn3.51732

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014013/
https://www.ncbi.nlm.nih.gov/pubmed/36728340
http://dx.doi.org/10.1002/acn3.51732

Ejemplares similares